Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>Despite an impressive amount of data, no particular class of agents — as monotherapy or in combination — provided distinct advantages for risk reduction of cardiovascular events or mortality.</p>

Many Treatment Choices for Type 2 Diabetes